David Steybe1, Maximilian Frederik Russe2, Ute Ludwig3, Tanja Sprave4, Kirstin Vach5, Wiebke Semper-Hogg1, Rainer Schmelzeisen1, Pit Jacob Voss1, Philipp Poxleitner1,6. 1. Department of Oral and Maxillofacial Surgery, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 2. Department of Diagnostic and Interventional Radiology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 3. Medical Physics, Department of Radiology, Faculty of Medicine, Medical Center - University of Freiburg, University of Freiburg, Freiburg, Germany. 4. Department of Radiation Oncology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 5. Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg, Freiburg, Germany. 6. Berta-Ottenstein-Programme for Clinician Scientists, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Abstract
OBJECTIVE: To evaluate a novel liquid fiducial marker for intraoperative marking of the tumour resection surface in oral cancer patients to facilitate precise postoperative delineation of the interface between the tumour resection border and reconstructed tissue for intensity-modulated radiation therapy. METHODS: A total of 200 markers were created by injecting the volumes of 10 µl, 20 µl, 30 µl, 40 µl and 50 µl of a liquid marker composed of sucrose acetoisobutyrate (SAIB) and iodinated sucrose acetoisobutyrate (x-SAIB) into the soft tissue of porcine mandible segments. Visibility of the resulting markers was quantified by threshold-based segmentation of the marker volume in CT- and CBCT imaging and by a comparison of signal intensities in MRI. RESULTS: Even the lowest volume of SAIB-/x-SAIB investigated (10 µl) resulted in a higher visibility (CTSoft tissue: 88.18 ± 13.23 µl; CTBone: 49.55 ± 7.62 µl; CBCT: 54.65 ± 12.58 µl) than observed with the incorporation of titanium ligature clips (CTSoft tissue: 50.15 ± 7.50 mm3; CTBone: 23.90 ± 3.39 mm3; CBCT: 33.80 ± 9.20 mm3). Markers created by the injection of 10 µl and 20 µl could reliably be delineated from markers created by the injection of higher volumes. CONCLUSION: SAIB/x-SAIB, which has recently become available as a Conformité Européenne (CE)-marked fiducial marker, provides an option for fast and reliable production of markers with excellent visibility in imaging modalities used in oral cancer radiation therapy (RT) planning routine.
OBJECTIVE: To evaluate a novel liquid fiducial marker for intraoperative marking of the tumour resection surface in oral cancer patients to facilitate precise postoperative delineation of the interface between the tumour resection border and reconstructed tissue for intensity-modulated radiation therapy. METHODS: A total of 200 markers were created by injecting the volumes of 10 µl, 20 µl, 30 µl, 40 µl and 50 µl of a liquid marker composed of sucrose acetoisobutyrate (SAIB) and iodinated sucrose acetoisobutyrate (x-SAIB) into the soft tissue of porcine mandible segments. Visibility of the resulting markers was quantified by threshold-based segmentation of the marker volume in CT- and CBCT imaging and by a comparison of signal intensities in MRI. RESULTS: Even the lowest volume of SAIB-/x-SAIB investigated (10 µl) resulted in a higher visibility (CTSoft tissue: 88.18 ± 13.23 µl; CTBone: 49.55 ± 7.62 µl; CBCT: 54.65 ± 12.58 µl) than observed with the incorporation of titanium ligature clips (CTSoft tissue: 50.15 ± 7.50 mm3; CTBone: 23.90 ± 3.39 mm3; CBCT: 33.80 ± 9.20 mm3). Markers created by the injection of 10 µl and 20 µl could reliably be delineated from markers created by the injection of higher volumes. CONCLUSION: SAIB/x-SAIB, which has recently become available as a Conformité Européenne (CE)-marked fiducial marker, provides an option for fast and reliable production of markers with excellent visibility in imaging modalities used in oral cancer radiation therapy (RT) planning routine.
Authors: Jonas Scherman Rydhög; Rasmus Irming Jølck; Thomas Lars Andresen; Per Munck Af Rosenschöld Journal: Med Phys Date: 2015-06 Impact factor: 4.071
Authors: Gerson M Struik; Nienke Hoekstra; Taco M Klem; Ali Ghandi; Gerda M Verduijn; Annemarie T Swaak-Kragten; Alja Schoonbeek; Kim C de Vries; Margriet A Sattler; Kees Verhoef; Erwin Birnie; Jean-Philippe Pignol Journal: Radiother Oncol Date: 2018-12-17 Impact factor: 6.280
Authors: Jonas Scherman Rydhög; Rosalind Perrin; Rasmus Irming Jølck; Francis Gagnon-Moisan; Klaus Richter Larsen; Paul Clementsen; Steen Riisgaard de Blanck; Gitte Fredberg Persson; Damien Charles Weber; Tony Lomax; Thomas Lars Andresen; Per Munck Af Rosenschold Journal: Radiother Oncol Date: 2017-01-16 Impact factor: 6.280
Authors: Anke M van Mourik; Paula H M Elkhuizen; Danny Minkema; Joop C Duppen; Corine van Vliet-Vroegindeweij Journal: Radiother Oncol Date: 2010-03-02 Impact factor: 6.280
Authors: Jonas Scherman Rydhög; Steen Riisgaard Mortensen; Klaus Richter Larsen; Paul Clementsen; Rasmus Irming Jølck; Mirjana Josipovic; Marianne Camille Aznar; Lena Specht; Thomas Lars Andresen; Per Munck Af Rosenschöld; Gitte Fredberg Persson Journal: Radiother Oncol Date: 2016-07-18 Impact factor: 6.280
Authors: David Steybe; Philipp Poxleitner; Pit Jacob Voss; Marc Christian Metzger; Rainer Schmelzeisen; Fabian Bamberg; Suam Kim; Maximilian Frederik Russe Journal: BMC Med Imaging Date: 2021-10-27 Impact factor: 1.930